Maintenance durvalumab after first-line chemotherapy in patients with HER2-negative advanced oesophago-gastric adenocarcinoma: results from the randomised PLATFORM study.

checkpoint inhibitor durvalumab gastric cancer maintenance therapy oesophageal adenocarcinoma

Journal

ESMO open
ISSN: 2059-7029
Titre abrégé: ESMO Open
Pays: England
ID NLM: 101690685

Informations de publication

Date de publication:
11 Jul 2024
Historique:
received: 19 03 2024
revised: 26 05 2024
accepted: 31 05 2024
medline: 14 7 2024
pubmed: 14 7 2024
entrez: 13 7 2024
Statut: aheadofprint

Résumé

PLAnning Treatment For Oesophago-gastric Cancer: a Randomised Maintenance Therapy Trial (PLATFORM) is an adaptive phase II study assessing the role of maintenance therapies in advanced oesophago-gastric (OG) adenocarcinoma. We evaluated the role of the anti-programmed death-ligand 1 (PD-L1) inhibitor durvalumab in these patients. Patients with human epidermal growth factor receptor 2-negative locally advanced or metastatic OG adenocarcinoma with disease control or response to 18 weeks of platinum-based first-line chemotherapy were randomised to active surveillance or maintenance durvalumab. The primary endpoint was progression-free survival (PFS). Safety was assessed in all patients who had commenced surveillance visits or received at least one dose of durvalumab. Exploratory survival analyses according to PD-L1 Combined Positive Score (CPS) and immune (biomarker-positive) or angiogenesis dominant (biomarker-negative) tumour microenvironment (TME) phenotypes were conducted. Between March 2015 and April 2020, 205 patients were randomised to surveillance (n = 100) and durvalumab (n = 105). No significant differences were seen in PFS [hazard ratio (HR) 0.84, P = 0.13] and overall survival (OS; HR 0.98, P = 0.45) between surveillance and durvalumab. Five patients randomised to durvalumab demonstrated incremental radiological responses compared with none with surveillance. Treatment-related adverse events occurred in 77 (76.2%) durvalumab-assigned patients. A favourable effect in OS with durvalumab over surveillance in CPS ≥5 and immune biomarker-positive patients was observed compared with CPS <5 and biomarker-negative subgroups, respectively: CPS ≥5 versus <5: HR 0.63, 95% confidence interval (CI) 0.32-1.22 versus HR 0.93, 95% CI 0.44-1.96; biomarker-positive versus negative: HR 0.60, 95% CI 0.29-1.23 versus HR 0.84, 95% CI 0.42-1.65. Maintenance durvalumab does not improve PFS in patients with OG adenocarcinoma who respond to first-line chemotherapy but induced incremental radiological responses in a subset of patients. TME characterisation could refine patient selection for anti-PD-L1 therapy above PD-L1 CPS alone.

Sections du résumé

BACKGROUND BACKGROUND
PLAnning Treatment For Oesophago-gastric Cancer: a Randomised Maintenance Therapy Trial (PLATFORM) is an adaptive phase II study assessing the role of maintenance therapies in advanced oesophago-gastric (OG) adenocarcinoma. We evaluated the role of the anti-programmed death-ligand 1 (PD-L1) inhibitor durvalumab in these patients.
PATIENTS AND METHODS METHODS
Patients with human epidermal growth factor receptor 2-negative locally advanced or metastatic OG adenocarcinoma with disease control or response to 18 weeks of platinum-based first-line chemotherapy were randomised to active surveillance or maintenance durvalumab. The primary endpoint was progression-free survival (PFS). Safety was assessed in all patients who had commenced surveillance visits or received at least one dose of durvalumab. Exploratory survival analyses according to PD-L1 Combined Positive Score (CPS) and immune (biomarker-positive) or angiogenesis dominant (biomarker-negative) tumour microenvironment (TME) phenotypes were conducted.
RESULTS RESULTS
Between March 2015 and April 2020, 205 patients were randomised to surveillance (n = 100) and durvalumab (n = 105). No significant differences were seen in PFS [hazard ratio (HR) 0.84, P = 0.13] and overall survival (OS; HR 0.98, P = 0.45) between surveillance and durvalumab. Five patients randomised to durvalumab demonstrated incremental radiological responses compared with none with surveillance. Treatment-related adverse events occurred in 77 (76.2%) durvalumab-assigned patients. A favourable effect in OS with durvalumab over surveillance in CPS ≥5 and immune biomarker-positive patients was observed compared with CPS <5 and biomarker-negative subgroups, respectively: CPS ≥5 versus <5: HR 0.63, 95% confidence interval (CI) 0.32-1.22 versus HR 0.93, 95% CI 0.44-1.96; biomarker-positive versus negative: HR 0.60, 95% CI 0.29-1.23 versus HR 0.84, 95% CI 0.42-1.65.
CONCLUSION CONCLUSIONS
Maintenance durvalumab does not improve PFS in patients with OG adenocarcinoma who respond to first-line chemotherapy but induced incremental radiological responses in a subset of patients. TME characterisation could refine patient selection for anti-PD-L1 therapy above PD-L1 CPS alone.

Identifiants

pubmed: 39002179
pii: S2059-7029(24)01391-7
doi: 10.1016/j.esmoop.2024.103622
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103622

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Auteurs

C Fong (C)

Gastrointestinal Unit, Department of Medicine, Royal Marsden Hospital, London and Surrey.

B Patel (B)

Gastrointestinal Unit, Department of Medicine, Royal Marsden Hospital, London and Surrey.

C Peckitt (C)

Research Data & Statistics Unit, Royal Marsden Clinical Trials Unit, Royal Marsden Hospital, London and Surrey.

E Bourmpaki (E)

Research Data & Statistics Unit, Royal Marsden Clinical Trials Unit, Royal Marsden Hospital, London and Surrey.

L Satchwell (L)

Research Data & Statistics Unit, Royal Marsden Clinical Trials Unit, Royal Marsden Hospital, London and Surrey.

S Cromarty (S)

Gastrointestinal Unit, Department of Medicine, Royal Marsden Hospital, London and Surrey.

S Kidd (S)

Gastrointestinal Unit, Department of Medicine, Royal Marsden Hospital, London and Surrey.

K von Loga (K)

Integrative Pathology Unit, Institute of Cancer Research, Sutton, UK.

M Uhlik (M)

Research and Biomarker Discovery, OncXerna Therapeutics, Inc., Waltham, USA.

R Begum (R)

Gastrointestinal Unit, Department of Medicine, Royal Marsden Hospital, London and Surrey.

T Rana (T)

Gastrointestinal Unit, Department of Medicine, Royal Marsden Hospital, London and Surrey.

T Waddell (T)

Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester.

S Darby (S)

Weston Park Cancer Centre, Sheffield.

A Bradshaw (A)

Cancer Services, The Freeman Hospital's Northern Centre for Cancer Care, Newcastle.

T Roques (T)

Department of Clinical Oncology, Norfolk and Norwich University Hospital, Norfolk & Norwich.

C Morgan (C)

Department of Clinical Oncology, Velindre Cancer Centre, Cardiff.

C Rees (C)

Cancer Care Division, Medical Oncology Department, University Hospital Southampton NHS Foundation Trust, Southampton.

R Herbertson (R)

Sussex Cancer Centre, Royal Sussex County Hospital, Brighton.

P Das (P)

Department of Oncology, University Hospitals of Derby and University of Nottingham School of Medicine.

C Thompson (C)

University Hospitals of Morecambe Bay NHS Foundation Trust, Kendal.

M Hewish (M)

Royal Surrey Cancer Centre, Royal Surrey Hospitals NHS Foundation Trust, Guildford.

R Petty (R)

Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Dundee.

F Thistlethwaite (F)

Department of Medical Oncology, The Christie NHS Foundation Trust and Division of Cancer Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, UK.

S Rao (S)

Gastrointestinal Unit, Department of Medicine, Royal Marsden Hospital, London and Surrey.

N Starling (N)

Gastrointestinal Unit, Department of Medicine, Royal Marsden Hospital, London and Surrey.

I Chau (I)

Gastrointestinal Unit, Department of Medicine, Royal Marsden Hospital, London and Surrey.

D Cunningham (D)

Gastrointestinal Unit, Department of Medicine, Royal Marsden Hospital, London and Surrey. Electronic address: david.cunningahm@rmh.nhs.uk.

Classifications MeSH